Literature DB >> 29095080

Prion and Prion-like Diseases in Humans: Poster Abstracts.

.   

Abstract

Entities:  

Keywords:  2D gel electrophoresis; Creutzfeldt-Jakob disease; Cu/Zn superoxide-dismutase1 (SOD1); EAE; LC-MS/MS; PrPC; amyotrophic lateral sclerosis (ALS); auditory stimulation; cryopreservation; cytoskeleton proteins; demyelination; differential regulation; dimerization; dura graft; epidemiology; fragmentation; iatrogenic Creutzfeldt-Jakob disease; inflammation; level of consciousness; liver; modeling; prion; prion diseases; prion protein; proteomics; reversible coma; somatic cell nuclear transfer (SCNT); storage; surveillance; swine model; temporal degradation; treatment; voice-recorded messages

Year:  2013        PMID： 29095080      PMCID： PMC4031668          DOI： 10.4161/pri.24865

Source DB:  PubMed          Journal:  Prion        ISSN： 1933-6896            Impact factor:   3.931


× No keyword cloud information.
  42 in total

1.  Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.

Authors:  Yuri Kawasaki; Keiichi Kawagoe; Chun-jen Chen; Kenta Teruya; Yuji Sakasegawa; Katsumi Doh-ura
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

2.  Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion.

Authors:  Ryuichiro Atarashi; Katsuya Satoh; Kazunori Sano; Takayuki Fuse; Naohiro Yamaguchi; Daisuke Ishibashi; Takehiro Matsubara; Takehiro Nakagaki; Hitoki Yamanaka; Susumu Shirabe; Masahito Yamada; Hidehiro Mizusawa; Tetsuyuki Kitamoto; Genevieve Klug; Amelia McGlade; Steven J Collins; Noriyuki Nishida
Journal:  Nat Med       Date:  2011-01-30       Impact factor: 53.440

3.  Heparin enhances the cell-protein misfolding cyclic amplification efficiency of variant Creutzfeldt-Jakob disease.

Authors:  Takashi Yokoyama; Atsuko Takeuchi; Miyuki Yamamoto; Tetsuyuki Kitamoto; James W Ironside; Masanori Morita
Journal:  Neurosci Lett       Date:  2011-05-05       Impact factor: 3.046

4.  Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease.

Authors:  J Gregor Sutcliffe; Peter B Hedlund; Elizabeth A Thomas; Floyd E Bloom; Brian S Hilbush
Journal:  J Neurosci Res       Date:  2011-03-03       Impact factor: 4.164

5.  The cellular prion protein modulates phagocytosis and inflammatory response.

Authors:  Cecília J G de Almeida; Luciana B Chiarini; Juliane Pereira da Silva; Patrícia M R E Silva; Marco Aurélio Martins; Rafael Linden
Journal:  J Leukoc Biol       Date:  2004-11-11       Impact factor: 4.962

6.  Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays.

Authors:  Jason M Wilham; Christina D Orrú; Richard A Bessen; Ryuichiro Atarashi; Kazunori Sano; Brent Race; Kimberly D Meade-White; Lara M Taubner; Andrew Timmes; Byron Caughey
Journal:  PLoS Pathog       Date:  2010-12-02       Impact factor: 6.823

7.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.

Authors:  H Büeler; M Fischer; Y Lang; H Bluethmann; H P Lipp; S J DeArmond; S B Prusiner; M Aguet; C Weissmann
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

8.  Peripheral amyloid-beta levels regulate amyloid-beta clearance from the central nervous system.

Authors:  Marcos A Marques; J Jacob Kulstad; Christopher E Savard; Pattie S Green; Sum P Lee; Suzanne Craft; G Stennis Watson; David G Cook
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Pathogenic mutations in the glycosylphosphatidylinositol signal peptide of PrP modulate its topology in neuroblastoma cells.

Authors:  Yaping Gu; Ajay Singh; Sharmila Bose; Neena Singh
Journal:  Mol Cell Neurosci       Date:  2008-01-26       Impact factor: 4.314

10.  Discovery of 2-aminothiazoles as potent antiprion compounds.

Authors:  Sina Ghaemmaghami; Barnaby C H May; Adam R Renslo; Stanley B Prusiner
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.